Concentrix Reports $1.52B Goodwill Impairment Leading to Significant Net Loss in Fiscal 2025 Annual Report
CNXC is trading near its 52-week low of $31.625 (15% above the low).
Summary
Concentrix Corp filed its annual 10-K, reporting a $1.52 billion non-cash goodwill impairment charge for fiscal year 2025, resulting in a net loss of $1.28 billion, despite a 2.2% increase in revenue.
Key Events · Earnings and Guidance · CNXC
-
Significant Goodwill Impairment
The company recorded a non-cash goodwill impairment charge of $1,523.3 million for the fiscal year ended November 30, 2025. This was determined after an interim quantitative assessment on November 1, 2025, following a sustained decrease in the market price of its common stock.
-
Substantial Net Loss
Concentrix reported a net loss of $(1,278.9) million for fiscal year 2025, a significant decline from a net income of $251.2 million in fiscal year 2024, primarily due to the goodwill impairment.
-
Modest Revenue Growth
Revenue increased by 2.2% to $9,825.8 million in fiscal year 2025, up from $9,618.9 million in the prior fiscal year.
-
Increased Share Repurchase Authorization
The board of directors extended the share repurchase program in January 2025, increasing the remaining authorization to $600 million. As of November 30, 2025, approximately $439.5 million remained available for repurchases.
Analysis · CNXC · Trade & Services
Concentrix Corp's annual 10-K filing reveals a substantial non-cash goodwill impairment charge of $1.52 billion for fiscal year 2025, which was the primary driver of a net loss of $1.28 billion. This impairment, triggered by a sustained decrease in the company's stock price, indicates a significant re-evaluation of the carrying value of assets from past acquisitions. While the company achieved a modest 2.2% revenue growth, the impairment overshadows operational performance. Investors should note the material impact on the company's financial position and the underlying challenges reflected by the asset write-down. The company also increased its share repurchase authorization and made debt repayments, but these are secondary to the impairment's magnitude.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNXC was trading at $36.32 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $31.63 to $66.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.